초록 ▼

A composition for administration to the mucosa comprises a pharmacologically active compound and a polycationic substance. The polycationic substance is preferably DEAE-dextran or chitosan and the pharmacologically active compound is preferably insulin or calcitonin. The composition may be a solutio

A composition for administration to the mucosa comprises a pharmacologically active compound and a polycationic substance. The polycationic substance is preferably DEAE-dextran or chitosan and the pharmacologically active compound is preferably insulin or calcitonin. The composition may be a solution, dispersion, powder or microspheres. Other enhancers, such as lysophosphatidylcholine, can be included if desired.

대표청구항 ▼

A method of systemically delivering a pharmaceutically effective amount of a pharmacologically active compound to a mammal comprising: administering to a mucosal surface a composition including a pharmacologically active compound in a pharmaceutically effective amount when administered systemically

A method of systemically delivering a pharmaceutically effective amount of a pharmacologically active compound to a mammal comprising: administering to a mucosal surface a composition including a pharmacologically active compound in a pharmaceutically effective amount when administered systemically and a polymeric substance having a plurality of cationic groups having a molecular weight of 10,000 or more providing for absorption of the active compound across the mucosal surface of the mammal for systemic distribution of the active compound, wherein the polymeric substance is selected from the group consisting of polycationic carbohydrates, polyaminoacids, polyquaternary compounds, protamine, polyimines, polymers having a cationic DEAE group, polyvinylpyridine, polymethacrylates, polyacrylates, polyoxethanes, polyamidoamines, polythiodiethylamino methylethylene, and poly-p-aminostyrene, and (i) the substance is not a polyamino acid which chelates calcium or magnesium ions, (ii) the composition does not consist of microcapsules coated with DEAE-dextran, (iii) if for administration to gut mucosa, the composition does not consist of the active compound and a solution of DEAE-dextran, and (iv) if in the form of a tablet for retention in the mouth, the composition does not comprise chitosan, and allowing the composition to remain in contact with mucosa for a time sufficient for a pharmaceutically effective amount of the pharmacologically active compound to pass through the mucosa.